FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2921836804> ?p ?o ?g. }

• W2921836804 endingPage "341" @default.
• W2921836804 startingPage "341" @default.
• W2921836804 abstract "Recent findings suggest that a fraction of EGFR-mutant non-small-cell lung cancers (NSCLC) carry additional driver mutations that could potentially affect the activity of EGFR tyrosine kinase inhibitors (TKIs). We investigated the role of concomitant KRAS, NRAS, BRAF, PIK3CA, MET and ERBB2 mutations (other mutations) on the outcome of 133 EGFR mutant patients, who received first-line therapy with EGFR TKIs between June 2008 and December 2014. Analysis of genomic DNA by Next Generation Sequencing (NGS) revealed the presence of hotspot mutations in genes other than the EGFR, including KRAS, NRAS, BRAF, ERBB2, PIK3CA, or MET, in 29/133 cases (21.8%). A p.T790M mutation was found in 9/133 tumour samples (6.8%). The progression free survival (PFS) of patients without other mutations was 11.3 months vs. 7 months in patients with other mutations (log-rank test univariate: p = 0.047). In a multivariate Cox regression model including the presence of other mutations, age, performance status, smoking status, and the presence of p.T790M mutations, the presence of other mutations was the only factor significantly associated with PFS (Hazard Ratio 1.63, 95% CI 1.04⁻2.58; p = 0.035). In contrast, no correlation was found between TP53 mutations and patients' outcome. These data suggest that a subgroup of EGFR mutant tumours have concomitant driver mutations that might affect the activity of first-line EGFR TKIs." @default.
• W2921836804 created "2019-03-22" @default.
• W2921836804 creator A5002665417 @default.
• W2921836804 creator A5002867055 @default.
• W2921836804 creator A5003014678 @default.
• W2921836804 creator A5008403882 @default.
• W2921836804 creator A5013429068 @default.
• W2921836804 creator A5015740152 @default.
• W2921836804 creator A5021158045 @default.
• W2921836804 creator A5023104040 @default.
• W2921836804 creator A5023150524 @default.
• W2921836804 creator A5031019737 @default.
• W2921836804 creator A5036367394 @default.
• W2921836804 creator A5038198711 @default.
• W2921836804 creator A5039134651 @default.
• W2921836804 creator A5048720703 @default.
• W2921836804 creator A5051933262 @default.
• W2921836804 creator A5062149201 @default.
• W2921836804 creator A5064397451 @default.
• W2921836804 creator A5065811679 @default.
• W2921836804 creator A5075514238 @default.
• W2921836804 creator A5078588212 @default.
• W2921836804 date "2019-03-10" @default.
• W2921836804 modified "2023-10-16" @default.
• W2921836804 title "The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients" @default.
• W2921836804 cites W1484806995 @default.
• W2921836804 cites W1692939660 @default.
• W2921836804 cites W1943756471 @default.
• W2921836804 cites W1990013637 @default.
• W2921836804 cites W1992364688 @default.
• W2921836804 cites W1999352980 @default.
• W2921836804 cites W2003910713 @default.
• W2921836804 cites W2005074076 @default.
• W2921836804 cites W2016180814 @default.
• W2921836804 cites W2050369944 @default.
• W2921836804 cites W2091308569 @default.
• W2921836804 cites W2096540669 @default.
• W2921836804 cites W2098395191 @default.
• W2921836804 cites W2120111652 @default.
• W2921836804 cites W2123926833 @default.
• W2921836804 cites W2133283856 @default.
• W2921836804 cites W2139799027 @default.
• W2921836804 cites W2154974159 @default.
• W2921836804 cites W2155014687 @default.
• W2921836804 cites W2167934111 @default.
• W2921836804 cites W2170899818 @default.
• W2921836804 cites W2182664595 @default.
• W2921836804 cites W2256274387 @default.
• W2921836804 cites W2297501306 @default.
• W2921836804 cites W2336491212 @default.
• W2921836804 cites W2340056105 @default.
• W2921836804 cites W2416111151 @default.
• W2921836804 cites W2534288116 @default.
• W2921836804 cites W2569813883 @default.
• W2921836804 cites W2609243345 @default.
• W2921836804 cites W2655216406 @default.
• W2921836804 cites W2683488101 @default.
• W2921836804 cites W2794883050 @default.
• W2921836804 cites W2804482009 @default.
• W2921836804 cites W2805663018 @default.
• W2921836804 cites W2890760483 @default.
• W2921836804 doi "https://doi.org/10.3390/cancers11030341" @default.
• W2921836804 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6468673" @default.
• W2921836804 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30857358" @default.
• W2921836804 hasPublicationYear "2019" @default.
• W2921836804 type Work @default.
• W2921836804 sameAs 2921836804 @default.
• W2921836804 citedByCount "42" @default.
• W2921836804 countsByYear W29218368042019 @default.
• W2921836804 countsByYear W29218368042020 @default.
• W2921836804 countsByYear W29218368042021 @default.
• W2921836804 countsByYear W29218368042022 @default.
• W2921836804 countsByYear W29218368042023 @default.
• W2921836804 crossrefType "journal-article" @default.
• W2921836804 hasAuthorship W2921836804A5002665417 @default.
• W2921836804 hasAuthorship W2921836804A5002867055 @default.
• W2921836804 hasAuthorship W2921836804A5003014678 @default.
• W2921836804 hasAuthorship W2921836804A5008403882 @default.
• W2921836804 hasAuthorship W2921836804A5013429068 @default.
• W2921836804 hasAuthorship W2921836804A5015740152 @default.
• W2921836804 hasAuthorship W2921836804A5021158045 @default.
• W2921836804 hasAuthorship W2921836804A5023104040 @default.
• W2921836804 hasAuthorship W2921836804A5023150524 @default.
• W2921836804 hasAuthorship W2921836804A5031019737 @default.
• W2921836804 hasAuthorship W2921836804A5036367394 @default.
• W2921836804 hasAuthorship W2921836804A5038198711 @default.
• W2921836804 hasAuthorship W2921836804A5039134651 @default.
• W2921836804 hasAuthorship W2921836804A5048720703 @default.
• W2921836804 hasAuthorship W2921836804A5051933262 @default.
• W2921836804 hasAuthorship W2921836804A5062149201 @default.
• W2921836804 hasAuthorship W2921836804A5064397451 @default.
• W2921836804 hasAuthorship W2921836804A5065811679 @default.
• W2921836804 hasAuthorship W2921836804A5075514238 @default.
• W2921836804 hasAuthorship W2921836804A5078588212 @default.
• W2921836804 hasBestOaLocation W29218368041 @default.
• W2921836804 hasConcept C104317684 @default.
• W2921836804 hasConcept C121608353 @default.
• W2921836804 hasConcept C126322002 @default.

• next